KDR and clear cell renal carcinoma: The results of a biomarker-driven, open-label, non-comparative, randomised phase 2 trial [28] show that a prospective patient selection based on the molecular phenotype of the tumor is possible, and has a positive effect on choosing the most effective treatment (between nivolumab, with or without ipilimumab, and a VEGFR-TKI) in the first-line treatment of metastatic clear-cell renal cell carcinoma.